Filana Therapeutics, Inc.
FLNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001069530
No open-market purchases or sales by Filana Therapeutics, Inc. insiders were filed in the last 90 days; 85 institutions reported holding it in 13F filings for Q2 2026, worth $15.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −15 vs. previous quarter
- 85
- 13F valueReported value at the end of Q2 2026
- $15.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding FLNA, Q2 2026
No superinvestor reported holding FLNA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Filana Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2025 (view filing) | Nov 24 | 1 day | Anderson Robert Eugene JrDirector | PPurchase | +8.60K | $2.90 | +$24.9K | New position8.60K after | |
| Nov 24, 2025 (view filing) | Nov 20 | 4 days | Barry RichardPresident & CEO | PPurchase | +150.0K | $2.76 | +$414.0K | +19.0%938.1K after | |
| Nov 20, 2025 (view filing) | Nov 19 | 1 day | Barry RichardPresident & CEO | PPurchase | +73.4K | $2.75 | +$201.8K | +10.3%788.1K after | |
| Oct 2, 2025 (view filing) | Sep 30 | 2 days | Cook Robert ChristopherChief Operating & Legal Office | PPurchase | +13.7K | $2.91 | +$39.9K | New position13.7K after | |
| Sep 23, 2025 (view filing) | Sep 22 | 1 day | Barry RichardPresident & CEO | PPurchase | +7.17K | $2.28 | +$16.4K | +1.0%714.7K after | |
| Sep 22, 2025 (view filing) | Sep 18-19 | 4 days | Barry RichardPresident & CEO | PPurchase | +237.9K | $2.25 | +$534.7K | +50.7%707.5K after | 4 lots |
| Dec 3, 2024 (view filing) | Nov 29 | 4 days | Kupiec James WilliamChief Medical Officer | SSale | −4.00K | $3.87 | −$15.5K | −100.0%0 after | |
| Dec 3, 2024 (view filing) | Nov 29 | 4 days | Schoen EricChief Financial Officer | SSale | −2.00K | $3.82 | −$7.64K | −100.0%0 after | |
| Dec 3, 2024 (view filing) | Nov 29 | 4 days | Schoen EricChief Financial Officer | SSale | −59.8K | $3.86 | −$230.8K | −83.9%11.5K after | |
| Aug 24, 2023 (view filing) | Aug 23 | 1 day | Robertson SanfordDirector | PPurchase | +30.0K | $17.45 | +$523.5K | +3.5%886.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Filana Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,974,981 | $2.35M | 0.00% | +44,038+2.3% | Added |
| Two Sigma Investments, LP | 1,711,358 | $2.04M | 0.00% | −277,456−14.0% | Reduced |
| Marshall Wace, LLP | 1,597,548 | $1.90M | 0.00% | −414,995−20.6% | Reduced |
| BlackRock, Inc. | 1,453,561 | $1.73M | 0.00% | +39,047+2.8% | Added |
| Goldman Sachs Group Inc | 668,792 | $795.9K | 0.00% | +627,468+1,518.4% | Added |
| Geode Capital Management, LLC | 615,510 | $732.7K | 0.00% | +19,268+3.2% | Added |
| D. E. Shaw & Co., Inc. | 485,025 | $577.2K | 0.00% | −74,180−13.3% | Reduced |
| GMT Capital Corp | 450,100 | $535.6K | 0.03% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 389,601 | $463.6K | 0.00% | +62,842+19.2% | Added |
| Squarepoint Ops LLC | 318,380 | $378.9K | 0.00% | +318,380 | New |